Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug Drysdale. “In addition to our clinical work, we have been actively broadening our robust IP portfolio through securing strategic licensing agreements for preclinical psychedelic-based compounds that will support our ongoing drug development efforts. These recent initiatives will also pave the way for Cybin to continue to pursue the potential creation of safe and effective therapeutics for patients facing the challenges of mental health conditions.”
In addition, the company today announced that it presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003, at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”), taking place Nov. 12-16, 2022, in San Diego, California. “It is exciting to be part of this year’s SFN meeting and showcase CYB003 amongst leading scientists and academics in the area of psychedelic medicine,” said Cybin’s Head of Research & Development Geoff Varty, Ph.D. “Our presentation at Neuroscience 2022 highlighted the findings from our CYB003 preclinical studies. Compared to classical psilocybin, CYB003 has demonstrated less variability in plasma levels, faster onset of action and shorter duration of effect. These potential therapeutic benefits could result in reduced time and resource burden on the health care system and potentially improved scalability and accessibility of treatment.”
To view the full press releases, visit https://ibn.fm/NySwl and https://ibn.fm/Zdwbq
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
